The MiningNewsWire Podcast

NetworkNewsWire Editorial Coverage: Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer’s, Parkinson’s, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

• GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
• Lexaria Bioscience is utilizing its patented DehydraTECH drug-delivery platform to improve the way active molecules enter the bloodstream upon oral ingestion.
• A pilot study showed that a DehydraTECH-processed form of blockbuster Rybelsus (a GLP-1) was more effective controlling blood glucose than standard Rybelsus.
• Lexaria recently received final data from the study and plans to conduct additional human studies during Q1 2024.

Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial.

NetworkNewsWire Editorial Coverage: Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer’s, Parkinson’s, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

• GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
• Lexaria Bioscience is utilizing its patented DehydraTECH drug-delivery platform to improve the way active molecules enter the bloodstream upon oral ingestion.
• A pilot study showed that a DehydraTECH-processed form of blockbuster Rybelsus (a GLP-1) was more effective controlling blood glucose than standard Rybelsus.
• Lexaria recently received final data from the study and plans to conduct additional human studies during Q1 2024.

Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial.

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the recommendation of the independent Data Safety Monitoring Board (DSMB) that the Company’s ongoing global, potentially pivotal trial of the investigational agent, Berubicin for the treatment of glioblastoma multiforme (GBM) continue without any modification.

The recommendation follows the DSMB’s pre-specified futility analysis of unblinded (to the DSMB only) efficacy and safety data in the Company’s trial of Berubicin versus Lomustine, a standard of care in patients with recurrent GBM. More specifically, the DSMB reviewed the primary endpoint of overall survival (OS) and secondary efficacy measures progression-free survival (PFF) and overall response rate (ORR), as well as safety data in evaluable patients. In order to support continuing the trial, Berubicin’s efficacy had to be at least comparable to Lomustine’s on the primary endpoint (OS).

To read the original press release, visit: https://www.nnw.fm/Sj7iP

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the recommendation of the independent Data Safety Monitoring Board (DSMB) that the Company’s ongoing global, potentially pivotal trial of the investigational agent, Berubicin for the treatment of glioblastoma multiforme (GBM) continue without any modification.

The recommendation follows the DSMB’s pre-specified futility analysis of unblinded (to the DSMB only) efficacy and safety data in the Company’s trial of Berubicin versus Lomustine, a standard of care in patients with recurrent GBM. More specifically, the DSMB reviewed the primary endpoint of overall survival (OS) and secondary efficacy measures progression-free survival (PFF) and overall response rate (ORR), as well as safety data in evaluable patients. In order to support continuing the trial, Berubicin’s efficacy had to be at least comparable to Lomustine’s on the primary endpoint (OS).

To read the original press release, visit: https://www.nnw.fm/Sj7iP

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

NetworkNewsWire Editorial Coverage: The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria’s heavily-patented DehydraTECH drug delivery technology might  improve bioavailability, lower costs, and enhance tolerability, weight-loss potential and management of diabetes and other health conditions. DehydraTECH may become a game changer in the multibillion-dollar GLP-1 drug market and could potentially lead to a collaboration with a dominant player in the space, such as Novo Nordisk (NYSE: NVO, Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), or AstraZeneca PLC (NASDAQ: AZN).

• Lexaria’s DehydraTECH is easily integrated into oral product manufacturing processes to better deliver API payloads to improve bioavailability, reduce side effects and more.
• Lexaria is evaluating the impact of DehydraTECH on oral performance of GLP-1 drugs for diabetes and weight loss, a market forecast to reach up to an astonishing $200 billion per year.
• DehydraTECH is a scalable technology for a multitude of applications that has separately been licensed by Altria for oral nicotine products.
• DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

NetworkNewsWire Editorial Coverage: The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria’s heavily-patented DehydraTECH drug delivery technology might  improve bioavailability, lower costs, and enhance tolerability, weight-loss potential and management of diabetes and other health conditions. DehydraTECH may become a game changer in the multibillion-dollar GLP-1 drug market and could potentially lead to a collaboration with a dominant player in the space, such as Novo Nordisk (NYSE: NVO, Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), or AstraZeneca PLC (NASDAQ: AZN).

• Lexaria’s DehydraTECH is easily integrated into oral product manufacturing processes to better deliver API payloads to improve bioavailability, reduce side effects and more.
• Lexaria is evaluating the impact of DehydraTECH on oral performance of GLP-1 drugs for diabetes and weight loss, a market forecast to reach up to an astonishing $200 billion per year.
• DehydraTECH is a scalable technology for a multitude of applications that has separately been licensed by Altria for oral nicotine products.
• DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Longeveron’s recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, CEO of Longeveron, stated in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B™ in this study population. With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™.”

To read the original press release, visit: https://nnw.fm/ckhHp

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Longeveron’s recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, CEO of Longeveron, stated in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B™ in this study population. With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™.”

To read the original press release, visit: https://nnw.fm/ckhHp

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

In volatile economic conditions, smart money seeks stability and moves to safe havens. Historically, one of the safest places and most stable spaces during economic uncertainty is gold, a highly liquid asset that preserves and even increases in value over time and carries no credit risk. The precious metal benefits from multiple levers of demand such as gold jewelry, tech/industrial use and a reserve asset as well as a strategic investment. History has shown that gold’s variable demand pressures enhance a portfolio by improving diversification, providing liquidity and delivering long-term returns. Reacting to uncertainties, many gold mining companies, including GEMXX Corp. (OTC: GEMZ) (profile), have enjoyed significant growth during the recent volatility. Exploding past startup phase and achieving global growth in mere months, GEMXX is fast approaching a holy grail that differentiates GEMXX from all others in the gold space – a vertically integrated mining company – a unique mine-to-market enterprise that specializes in gold and gemstone mining as well as jewelry creation, production and global sales. GEMXX owns and controls every aspect of the process from gold mining and gemstone finishing to jewelry manufacturing and global distribution. Other larger mining companies may not have the unique vertical integration of GEMXX but are still seeing success in the precious metal sector including Agnico Eagle Mines Ltd. (NYSE: AEM), which recently reported record second-quarter numbers; Barrick Gold (NYSE: GOLD), which anticipates a second half of the year performance that surpasses its first; Newmont Mining (NYSE: NEM), which has received required approvals on a key acquisition announced earlier this year; and Franco-Nevada Corp. (NYSE: FNV), which has established a business model that provides investors with gold price and exploration optionality while limiting exposure to cost inflation.

To view the full editorial, visit https://ibn.fm/trQPF

In volatile economic conditions, smart money seeks stability and moves to safe havens. Historically, one of the safest places and most stable spaces during economic uncertainty is gold, a highly liquid asset that preserves and even increases in value over time and carries no credit risk. The precious metal benefits from multiple levers of demand such as gold jewelry, tech/industrial use and a reserve asset as well as a strategic investment. History has shown that gold’s variable demand pressures enhance a portfolio by improving diversification, providing liquidity and delivering long-term returns. Reacting to uncertainties, many gold mining companies, including GEMXX Corp. (OTC: GEMZ) (profile), have enjoyed significant growth during the recent volatility. Exploding past startup phase and achieving global growth in mere months, GEMXX is fast approaching a holy grail that differentiates GEMXX from all others in the gold space – a vertically integrated mining company – a unique mine-to-market enterprise that specializes in gold and gemstone mining as well as jewelry creation, production and global sales. GEMXX owns and controls every aspect of the process from gold mining and gemstone finishing to jewelry manufacturing and global distribution. Other larger mining companies may not have the unique vertical integration of GEMXX but are still seeing success in the precious metal sector including Agnico Eagle Mines Ltd. (NYSE: AEM), which recently reported record second-quarter numbers; Barrick Gold (NYSE: GOLD), which anticipates a second half of the year performance that surpasses its first; Newmont Mining (NYSE: NEM), which has received required approvals on a key acquisition announced earlier this year; and Franco-Nevada Corp. (NYSE: FNV), which has established a business model that provides investors with gold price and exploration optionality while limiting exposure to cost inflation.

To view the full editorial, visit https://ibn.fm/trQPF

In the business world, one of the cardinal reasons for mergers and acquisitions (M&As) is the potential for synergistic growth. Successful companies usually measure this in terms of revenue streams, market share and product offerings. However, in the age of digital technology and globalization, a significant facet of growth potential is often found a company’s core customer base and digital reputation. Lucy Scientific Discovery (NASDAQ: LSDI) (Profile) is astutely following this road map utilized by hugely successful corporations by uniquely leveraging user bases to rapidly amplify shareholder value. This well-established, albeit counterintuitive, M&A strategy has been utilized by several major companies including Meta Platforms Inc. (NASDAQ: META), Microsoft Corp. (NASDAQ: MSFT), Amazon.com Inc. (NASDAQ: AMZN) and Apple Inc. (NASDAQ: AAPL) with the unconventional process producing results that vastly exceeded expected typical M&A metrics.

To view the full editorial, visit https://nnw.fm/vNVcN

In the business world, one of the cardinal reasons for mergers and acquisitions (M&As) is the potential for synergistic growth. Successful companies usually measure this in terms of revenue streams, market share and product offerings. However, in the age of digital technology and globalization, a significant facet of growth potential is often found a company’s core customer base and digital reputation. Lucy Scientific Discovery (NASDAQ: LSDI) (Profile) is astutely following this road map utilized by hugely successful corporations by uniquely leveraging user bases to rapidly amplify shareholder value. This well-established, albeit counterintuitive, M&A strategy has been utilized by several major companies including Meta Platforms Inc. (NASDAQ: META), Microsoft Corp. (NASDAQ: MSFT), Amazon.com Inc. (NASDAQ: AMZN) and Apple Inc. (NASDAQ: AAPL) with the unconventional process producing results that vastly exceeded expected typical M&A metrics.

To view the full editorial, visit https://nnw.fm/vNVcN

Knightscope, Inc. (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Knightscope’s recent announcement that Ascendiant Capital Markets LLC (“Ascendiant”) has initiated coverage on the company’s stock with a buy rating and a price target of $3.50 per share.

“This recognition from Ascendiant reflects their confidence in our innovative autonomous security solutions, our strong market position and our ability to deliver long-term value to our shareholders with a buy rating,” William Santana Li, chairman and CEO of Knightscope, stated in the news release. “The Rise of the Robots continues, and Wall Street is now taking notice that Knightscope has a unique set of disruptive technologies combining artificial intelligence, autonomy, robotics and electric vehicle technology.”

To read the original press release, visit: https://nnw.fm/E15kA

Knightscope, Inc. (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Knightscope’s recent announcement that Ascendiant Capital Markets LLC (“Ascendiant”) has initiated coverage on the company’s stock with a buy rating and a price target of $3.50 per share.

“This recognition from Ascendiant reflects their confidence in our innovative autonomous security solutions, our strong market position and our ability to deliver long-term value to our shareholders with a buy rating,” William Santana Li, chairman and CEO of Knightscope, stated in the news release. “The Rise of the Robots continues, and Wall Street is now taking notice that Knightscope has a unique set of disruptive technologies combining artificial intelligence, autonomy, robotics and electric vehicle technology.”

To read the original press release, visit: https://nnw.fm/E15kA

The transition from fossil fuels to electrification has created a huge increase in demand for rare earth oxides and demand is expected to get much larger. Rare earth oxides are irreplaceable elements integral to permanent magnets, critical components in electric vehicles and sustainable power generation equipment, especially windmills. About 90% of all permanent magnets are currently produced in China, which is now considering banning or restricting exports of technology to process and refine rare-earth elements. Beijing is also pondering provisions prohibiting or limiting exports of alloy technology used in making high performance magnets made from rare earths minerals. As the transition to a cleaner world grows, China is restricting exports of permanent magnets and related tech in favor of feeding domestic demand, thus strangling the global transition. Governments in North America and across the world have voiced extreme urgency in reshaping supply chains to reduce dependence upon China and achieve clean energy mandates. Only a few companies can be called leaders in a nascent yet potentially explosive market. Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) (Profile) stands out with its transformative technology, RapidSX(TM), for separating and purifying critical metals. Also in the hunt for market share in this burgeoning new market is MP Materials Corp. (NYSE: MP), Neo Performance Materials Inc. (TSX: NEO), Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) and Li-Cycle Holdings Corp. (NYSE: LICY), all of which have established footholds and expanding operations in a concerted effort to shift away from reliance upon China and achieve energy independence.

To view the full editorial, visit https://nnw.fm/v5C04

The transition from fossil fuels to electrification has created a huge increase in demand for rare earth oxides and demand is expected to get much larger. Rare earth oxides are irreplaceable elements integral to permanent magnets, critical components in electric vehicles and sustainable power generation equipment, especially windmills. About 90% of all permanent magnets are currently produced in China, which is now considering banning or restricting exports of technology to process and refine rare-earth elements. Beijing is also pondering provisions prohibiting or limiting exports of alloy technology used in making high performance magnets made from rare earths minerals. As the transition to a cleaner world grows, China is restricting exports of permanent magnets and related tech in favor of feeding domestic demand, thus strangling the global transition. Governments in North America and across the world have voiced extreme urgency in reshaping supply chains to reduce dependence upon China and achieve clean energy mandates. Only a few companies can be called leaders in a nascent yet potentially explosive market. Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) (Profile) stands out with its transformative technology, RapidSX(TM), for separating and purifying critical metals. Also in the hunt for market share in this burgeoning new market is MP Materials Corp. (NYSE: MP), Neo Performance Materials Inc. (TSX: NEO), Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) and Li-Cycle Holdings Corp. (NYSE: LICY), all of which have established footholds and expanding operations in a concerted effort to shift away from reliance upon China and achieve energy independence.

To view the full editorial, visit https://nnw.fm/v5C04

Slave Lake Zinc (CSE: SLZ) (the “Company”) has reviewed historic drill logs recently obtained for 13 drill holes reported by American Yellowknife Mines from drilling conducted in 1951 at the MCO targets on the west side of O’Connor Lake. Slave Lake has noted that pegmatites and pegmatitic granites have been documented in these holes. Pegmatites were reported and ranged from less than 1 meter to over 10 meters in drill section. Exploration in 1951 was designed to test for zinc-lead-copper mineralization at O’Connor Lake. There was no evaluation for lithium or tantalum-columbite mineralization which are now a necessity for electrification (green energy).

To view the full press release, visit https://nnw.fm/D2hyq

Slave Lake Zinc (CSE: SLZ) (the “Company”) has reviewed historic drill logs recently obtained for 13 drill holes reported by American Yellowknife Mines from drilling conducted in 1951 at the MCO targets on the west side of O’Connor Lake. Slave Lake has noted that pegmatites and pegmatitic granites have been documented in these holes. Pegmatites were reported and ranged from less than 1 meter to over 10 meters in drill section. Exploration in 1951 was designed to test for zinc-lead-copper mineralization at O’Connor Lake. There was no evaluation for lithium or tantalum-columbite mineralization which are now a necessity for electrification (green energy).

To view the full press release, visit https://nnw.fm/D2hyq

Sostravel.com S.p.A. (BIT: SOS) (OTCQB: SOSAF) announced its business plan following the release of strong financial results for 2022.

To read the original press release, visit: https://ibn.fm/XeRsq

“Sostravel.com offers investors a unique opportunity to gain exposure to global travel and digital travel services growth,” Edoardo Zarghetta, IR Advisor for Sostravel.com, stated in the news release. “Our robust financial profile with a strong track record of profitability and operating cash flow generation, combined with flexible cost structure, commitment to preserving cash and balancing cost controls with investments, is already catching investors’ attention.”

Sostravel.com announced a positive EBITDA margin in 2022 attained in a year where revenues grew by 47%. Based on these positive results, the company unveiled its business plan, detailing the strategy behind the doubling of revenues and the 173x EBITDA growth expected by 2027.

As explained in the news release, Sostravel.com intends to bolster its recent growth by selling high-margin, private-label offerings of digital travel to Sardinia, the Red Sea and Kenya via both internal and major third-party booking platforms. It also plans to expand its ‘Secret Village’ offering in Sardinia, which proved popular with travelers, and promote growth of its Lost Luggage Concierge services aimed at the protection and recovery of air passengers’ luggage. Finally, Sostravel.com aims to launch a traveler-centered telehealth solution via the sostravel app to better meet the needs of international tourists.

Sostravel.com S.p.A. (BIT: SOS) (OTCQB: SOSAF) announced its business plan following the release of strong financial results for 2022.

To read the original press release, visit: https://ibn.fm/XeRsq

“Sostravel.com offers investors a unique opportunity to gain exposure to global travel and digital travel services growth,” Edoardo Zarghetta, IR Advisor for Sostravel.com, stated in the news release. “Our robust financial profile with a strong track record of profitability and operating cash flow generation, combined with flexible cost structure, commitment to preserving cash and balancing cost controls with investments, is already catching investors’ attention.”

Sostravel.com announced a positive EBITDA margin in 2022 attained in a year where revenues grew by 47%. Based on these positive results, the company unveiled its business plan, detailing the strategy behind the doubling of revenues and the 173x EBITDA growth expected by 2027.

As explained in the news release, Sostravel.com intends to bolster its recent growth by selling high-margin, private-label offerings of digital travel to Sardinia, the Red Sea and Kenya via both internal and major third-party booking platforms. It also plans to expand its ‘Secret Village’ offering in Sardinia, which proved popular with travelers, and promote growth of its Lost Luggage Concierge services aimed at the protection and recovery of air passengers’ luggage. Finally, Sostravel.com aims to launch a traveler-centered telehealth solution via the sostravel app to better meet the needs of international tourists.